Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507607 | 1.00 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL207554 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL29374052 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL11436625 | 0.80 | MEN1 (0.42) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL27995840 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL29463737 | 0.76 | CYP3A4 (0.52) | ALDH1A1CYP3A4HPGDTDP1POLB | |
| SCHEMBL6137454 | 0.76 | MEN1 (0.36) | ALDH1A1POLBMEN1KMT2ANPC1 | |
| SCHEMBL93220 | 0.76 | CYP3A4 (0.52) | ALDH1A1CYP3A4HPGDTDP1POLB | |
| SCHEMBL4466979 | 0.75 | ALDH1A1 (0.56) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL22588550 | 0.74 | APLNR (0.47) | ALDH1A1CYP3A4HPGDABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924210-A | Preparation method of 2-iminothiazolidine-4-ketone compound | 赣南师范大学 | 2024-04-26 | — | — | CN | claimed |
| CN-117247409-A | 3-thio/seleno-phosphorylated imidazole derivative and synthetic method and application thereof | 曲阜师范大学 | 2023-12-19 | — | — | CN | claimed |
| CN-111471171-A | Aryl sulfonic acid intermediate, preparation method thereof and application thereof in synthesizing low-temperature-sensitivity additive for concrete | 江苏苏博特新材料股份有限公司 | 2020-07-31 | — | — | CN | claimed |
| CN-109265382-A | A kind of fluorine-containing thiocarbamates compound and its synthetic method | 湖北科技学院 | 2019-01-25 | — | — | CN | claimed |
| CN-107188866-A | A kind of synthetic method of the ketone compounds of polysubstituted thiazole 4 | 湖北科技学院 | 2017-09-22 | — | — | CN | claimed |
| CN-106966990-A | A kind of synthetic method of the polysubstituted ketone compounds of 2 thiocarbamoyl imidazole quinoline 4 | 湖北科技学院 | 2017-07-21 | — | — | CN | claimed |
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (WUXI) COMPANY, INC. (CN) | 2016-09-01 | — | — | US | claimed |
| EP-3034076-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | JC (Wuxi) COMPANY, Inc. (CN) | 2016-06-22 | — | — | EP | claimed |
| CN-105267967-A | Combined application of isothiocyanate-type compound and anti-cancer drug acting or affecting DNA | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2016-01-27 | — | — | CN | claimed |
| CN-104415332-A | Combined application between isothiocyanate-type compound and kinase inhibitor medicine in treatment of cancer | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2015-03-18 | — | — | CN | claimed |
| CN-104117064-A | Combined application of isothiocyanate compound and hormone medicine | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2014-10-29 | — | — | CN | claimed |
| WO-2010065329-A2 | NANOPARTICLES FOR CANCER TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | WO | claimed |
| US-20060241178-A1 | Compositions and methods for treating lung cancer | IMMUNEGUARD LLC (US) | 2006-10-26 | — | — | US | claimed |
| WO-2004060365-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER | AMERICAN HEALTH FOUNDATION (US) | 2004-07-22 | — | — | WO | claimed |
| US-12515188-B2 | Automated microreactor for effective optimization of high-speed chemical reaction, and method of optimizing high-speed chemical reaction therefor | POSTECH Research and Business Development Foundation (KR) | 2026-01-06 | — | — | US | disclosed |
| US-20250188046-A1 | ULTRAFAST FLOW SYNTHESIS OF FUNCTIONALIZED SULFONYL FLUORIDES AND SUBSEQUENT SUFEX CONNECTIONS VIA LITHIATED CHEMISTRY | POSTECH Research and Business Development Foundation (KR) | 2025-06-12 | — | — | US | disclosed |
| EP-3446689-B1 | ISOTHIOCYANATE COMPOUND FOR USE IN THE TREATMENT OF HYPERBILIRUBINEMIA | JC WUXI COMPANY INC (CN) | 2025-01-08 | — | — | EP | disclosed |
| EP-0416820-A2 | Novel compounds exhibiting a vasodilating activity and inhibitory activity for platelet aggregation and pharmaceutical compositions containing them | Hidaka, Hiroyoshi (JP) | 1991-03-13 | — | — | EP | disclosed |
| EP-0352812-A1 | Antiarthritic alpha-arylcarbamoyl cyanoacetic acid derivatives | Bristol-Myers Squibb Company (US) | 1990-01-31 | — | — | EP | disclosed |
| EP-0349243-A2 | Antiviral combinations and compounds therefor | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250175-A1 | COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE | CHUK, KIT, MKI67 | ALDH1A1 2081/4885CYP3A4 2452/4885HPGD 3624/4885 |
| US-20250188046-A1 | ULTRAFAST FLOW SYNTHESIS OF FUNCTIONALIZED SULFONYL FLUORIDES AND SUBSEQUENT SUFEX CONNECTIONS VIA LITHIATED CHEMISTRY | FGFR4, STS, FGFR1 | ALDH1A1 1626/4885CYP3A4 644/4885HPGD 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.